Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 20 February 2006
Oxford Biomedica announces board
appointment
Oxford BioMedica, a gene therapy company, announces that Mike McDonald has been promoted to the board as an executive director with immediate effect and he maintains his title of chief medical officer
Mike McDonald's primary responsibilities include the company's clinical development activities and regulatory affairs He has over 20 years of experience in clinical drug development and regulatory leadership
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
He joined Oxford BioMedica in September 2005 from Seattle Genetics, a US-based biotechnology company, where he was chief medical officer.
McDonald spent nine years with Eli Lilly serving as worldwide vice president, clinical research and medical affairs, and was previously at SmithKline Beecham for seven years where he was involved in worldwide clinical development, regulatory management and was a member of the pharmaceutical development strategy committee.
From these positions McDonald contributed to the successful registration and commercialisation of many important pharmaceuticals.
He received his medical degree from Edinburgh University, he is a member of the Royal College of Physicians in London, holds a diploma in pharmaceutical medicine and is a fellow of the Faculty of Pharmaceutical Physicians.
Commenting on the board appointment, Professor Alan Kingsman, chief executive of Oxford BioMedica, said: "Mike has already made a significant and valuable contribution to the company since joining last year and has been instrumental in the preparations for our planned Phase III trial of TroVax in renal cell carcinoma.
"We are delighted to welcome him to the board.".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
